These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23138447)

  • 1. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
    Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
    Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
    Borrás-Blasco J; Gracia-Pérez A; Rosique-Robles JD; Casterá ME; Abad FJ
    Expert Opin Biol Ther; 2014 Feb; 14(2):145-50. PubMed ID: 24359492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
    van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
    Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
    Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
    Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
    Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis.
    Wada T; Son Y; Ozaki Y; Nomura S; Iida H
    Mod Rheumatol; 2012 Nov; 22(6):824-30. PubMed ID: 22302136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.
    van der Heijde D; Klareskog L; Landewé R; Bruyn GA; Cantagrel A; Durez P; Herrero-Beaumont G; Molad Y; Codreanu C; Valentini G; Zahora R; Pedersen R; MacPeek D; Wajdula J; Fatenejad S
    Arthritis Rheum; 2007 Dec; 56(12):3928-39. PubMed ID: 18050208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.
    Matsuno H; Tomomitsu M; Hagino A; Shin S; Lee J; Song YW
    Ann Rheum Dis; 2018 Apr; 77(4):488-494. PubMed ID: 29259050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
    van Riel PL; Taggart AJ; Sany J; Gaubitz M; Nab HW; Pedersen R; Freundlich B; MacPeek D;
    Ann Rheum Dis; 2006 Nov; 65(11):1478-83. PubMed ID: 16464988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Zang C; Alvarez D; Fletcher T; Wajdula J; Yuasa H; Vlahos B
    Mod Rheumatol; 2013 Jul; 23(4):623-33. PubMed ID: 23011358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
    Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
    Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.